Transcript
Good afternoon, and welcome to the Cumberland Pharmaceuticals Second Quarter 2025 Financial Report and Company Update. This call is being recorded at the company's request and will be archived on its website for 1 year from today's date. I would now like to turn it over to Emily Kent, Account Manager at the Dalton Agency, who handles Cumberland's Communications. Emily, please proceed.
Hello, everyone, and thank you for joining us today. This afternoon, Cumberland issued a press release announcing its second quarter financial results. The release also provided an operational update, including key developments during the quarter. The release, which includes the related financial tables, can be found on the company's website. Management will share an overview of those financial results during today's call. They'll also provide an overall company update, including a discussion of Cumberland's brands, pipeline and partners. Participating in today's call are A.J. Kazimi, Cumberland's Chief Executive Officer; along with Todd Anthony, Vice President, Organizational Development; and John Hamm, Chief Financial Officer. Please keep in mind that their discussions may include some forward-looking statements as defined in the Private Securities Reform Act. Those statements reflect the company's current views and expectations concerning future events and may involve risks as well as uncertainties. There are many factors that could affect Cumberland's future results, including natural disasters, economic downturns, public health, epidemics, international conflicts, trade restrictions and others that are beyond the company's control. Those issues are described under the caption Risk Factors in Cumberland's Form 10-K and any additional updates filed with the SEC. Any forward-looking statements made during today's call are qualified by those risk factors. Despite the company's best efforts, actual results may differ materially from expectations. So information shared on this call should be considered current as of today only. Also, please remember that the company isn't responsible for updating any forward-looking statements, whether as a result of new information or due to future developments. During today's call, there will be references to several of Cumberland's marketed brands. Full prescribing and safety information for each brand is included on the individual product websites, and you can find links to those sites on the corporate website. The company will also be providing some non-GAAP financial measures with respect to its performance. An explanation and reconciliation to GAAP measures can be found in the financial tables of the earnings release issued earlier this afternoon. If you have any questions, please hold them until the end of the call, at which point, we'll be happy to answer them. Management is also prepared to hold a follow-up conversation with shareholders after the call, if you prefer.
Thank you, Emily, and good afternoon, everyone. We appreciate you joining us today. As Emily mentioned, during the call, we'll provide a review of our financial results for the second quarter, and we'll also discuss the key developments that have occurred during the period. So let's get started. We've enjoyed a strong first half of the year. There were a series of positive developments during the second quarter, which we'll discuss today that bolster our optimistic view about the company's future. Earlier this year, we announced positive top line results from the Phase II study evaluating our ifetroban product candidate in patients with Duchenne muscular dystrophy or DMD. In June, those breakthrough findings were presented at the Parent Project Muscular Dystrophy Annual Conference, and they demonstrated that high-dose ifetroban delivered a 5.4% improvement in cardiac functions in the patients with DMD. The June presentation also included additional biomarker data indicating reduced cardiac damage, which correlated with the clinical findings. These results position ifetroban as a potential treatment for DMD cardiomyopathy, the leading cause of death in these patients and a critical unmet medical need affecting 90% of DMD patients by age 18. The FIGHT DMD study findings were previously selected for a late-breaking presentation in March at the Muscular Dystrophy Association's Clinical and Scientific Conference, which underscores the significant interest in our approach. In June, we completed the comprehensive analysis of the trial results. We prepared our clinical study report and then submitted that report to the FDA. We followed with a request for an end of Phase II meeting. We're very appreciative of the FDA's prompt response, and we are scheduled to meet with them this fall to discuss our clinical program and also discuss the development pathway forward. Meanwhile, we previously shared that our potential antibiotic Vibativ received approval from the regulatory authorities in China. That milestone provides us with access to the world's second largest pharmaceutical market, and we're now preparing to support the launch of Vibativ there. We also shared a new partnership with Saudi-based Tabuk Pharmaceuticals to introduce Vibativ into the Middle East. We began shipping Vibativ there, and we've completed the training required to launch the product in that country. Turning to our second quarter financial results. I'm pleased to report our portfolio of FDA-approved brands delivered combined revenues of $10.8 million during the quarter, a 10% increase over the same period last year. Year-to-date revenues for the first 6 months of the year totaled $22.6 million, a 23% increase over the prior year period. Adjusted earnings for the second quarter were $0.4 million. And for the first half of this year, adjusted earnings were $2.8 million or $0.18 a share, up significantly from the same period last year. In addition, our business generated $4.7 million in cash flow from operations during the first 6 months of 2025. On our balance sheet, we held $68 million in total assets, including $16 million in cash and cash equivalents. Liabilities were $40 million and shareholders' equity totaled $28 million, all at the end of the quarter. So with that overview, I'd now like to turn to Todd Anthony, Cumberland's Vice President, Organizational Development, to discuss both our brands and our sales organization.
Thank you, A.J. I will begin by providing an update on our major brands. Vibativ is our intravenous antibiotic aimed at treating difficult infections like hospital-acquired pneumonia, ventilator-associated pneumonia, and complicated skin infections caused by resistant gram-positive bacteria. The World Health Organization's report from 2024 indicates that antimicrobial resistance is becoming an urgent global health crisis, threatening the effectiveness of existing antibiotics. Unlike many antibiotics that struggle against bacteria, Vibativ employs a dual action approach specifically targeting drug-resistant strains, presenting significant life-saving potential as a solution amid this antibiotic resistance crisis and a weakened pipeline for new antibiotic developments. To emphasize this, we are initiating discussions with infectious disease experts across the country to promote Vibativ as a viable option for patients not responding to other treatments. Additionally, a new pharmacokinetic analysis published in Antimicrobial Agents and Chemotherapy examined data from over 1,200 patients, confirming tailored dosing strategies for varying infection severities and kidney functions, which underscores Vibativ's essential role in addressing severe gram-positive infections. We also recently made the Vibativ 4-Vial Starter Pak available through a distribution agreement with Vizient, which serves over 65% of acute care providers in the country, ensuring nationwide access and flexible treatment initiation in both inpatient and outpatient settings. Next, regarding Kristalose, our prescription laxative which comes in a pre-measured powder that quickly dissolves in water, we have observed the brand performs particularly well in states with Medicaid coverage. We are updating marketing materials and forming new specialty distribution partnerships to enhance patient access. Moving on to Caldolor, our intravenous ibuprofen, with FDA clearance for pediatric labeling, it is now the sole non-opioid product approved for pain treatment in infants via injection. Marketing efforts are highlighting this new indication, leading to increased usage in children's hospitals. In May, we published a study in Clinical Therapeutics showcasing Caldolor's safety and efficacy in managing postoperative pain in older patients, marking the first evaluation in this vulnerable demographic where traditional opioids may pose heightened risks. Now, regarding Sancuso, the only FDA-approved transdermal patch for chemotherapy-induced nausea, we are seeing positive sales outcomes following our oncology sales force expansion. We have revised our sampling program to increase patient trials and are refining our messaging to connect more effectively with healthcare providers and patients. We are also introducing new hub services to enhance patient support, including insurance authorization and co-pay assistance. Lastly, with Vaprisol, the only intravenously administered vasopressin receptor antagonist for treating hyponatremia in hospitalized patients, our new manufacturing partner is ready to produce the product and is awaiting FDA inspection of their facility. Once cleared, we will file for approval to manufacture branded Vaprisol there. That concludes my updates for today, A.J. I will pass it back to you.
Thank you, Todd. I'd now like to provide an update on our ongoing clinical activities. We continue to progress our pipeline of innovative products designed to improve patient care and their quality of life. Our ifetroban product candidate, a potent and selective thromboxane receptor antagonist, is being evaluated in several Phase II clinical trials for patients with a series of unmet medical needs. It's now been dosed in nearly 1,400 subjects and has been found to be safe and well tolerated in those individuals, resulting in an outstanding safety database for the product. I mentioned the favorable results from our Phase II study in patients with Duchenne muscular dystrophy. In addition, we've been evaluating ifetroban in another Phase II clinical program in patients with systemic sclerosis or scleroderma. It's the deadliest of the autoimmune diseases. Enrollment in this study was completed earlier this year, and we're now monitoring the clinical sites in preparation to lock the database and begin evaluating the results. We do expect to announce top-line findings from this study later this year. We also have a Phase II clinical study, the fighting fibrosis trial, underway in patients with idiopathic pulmonary fibrosis, the most common form of progressive fibrosing interstitial lung disease. Patient enrollment is proceeding swiftly in this study in medical centers across the country. The study design does include both an interim safety analysis as well as an interim efficacy analysis. In May, we announced a partnership with Qureight, a core imaging laboratory developing deep learning image analytics, which is based in Cambridge, U.K. to enhance the outcome and output of data from our fighting fibrosis clinical trial. The partnership will utilize their advanced deep learning image analytic tools for complex lung disease applications to provide deeper insights into treatment efficacy and disease progression in our IPF clinical program. So in summary, we believe ifetroban, which is our first new chemical entity, has the potential to benefit many patients, and we look forward to sharing our further progress, including the results from additional company-sponsored studies as they emerge. So with that update on our clinical activities, I'd now like to look to our Chief Financial Officer, John Hamm, to review our second quarter and year-to-date financial results.
Thank you, A.J. For the three months ending June 30, 2025, net revenue from continuing operations was $10.8 million, marking a 10% increase compared to the same period last year. For the first half of the year, total revenue reached $22.6 million, which is a 23% increase over the first six months of 2024. In the second quarter of 2025, net revenue by product included $2.8 million for Kristalose, $3.1 million for Sancuso, $2.7 million for Vibativ, and $1.6 million for Caldolor. Year-to-date product revenue amounted to $6.2 million for Kristalose, $4.1 million for Vibativ, $5.4 million for Sancuso, and $2.9 million for Caldolor. Now, regarding our expenditures, total operating expenses for the second quarter were $11.6 million, bringing year-to-date expenses to $22 million. The net loss for the quarter was $0.7 million, which shows a significant improvement from the previous year. Year-to-date net income stood at $0.5 million, and when noncash expenses are added back, adjusted earnings were $2.8 million or $0.18 per share. It's also important to mention that the adjusted earnings do not consider the additional benefit of $0.3 million from Vibativ's cost of goods received during the second quarter due to the product acquisition. We are pleased to see that the inclusion of Vibativ and Sancuso in our portfolio continues to positively influence our financial performance. The Vibativ acquisition added a total of $34 million in new assets, which includes approximately $21 million in inventory, $12 million in intangible assets, and $1 million in goodwill. The estimated value of these assets was $10.4 million at the end of the second quarter. The financial terms for the Vibativ transaction included a $20 million payment at closing and a subsequent $5 million milestone payment. We also continue to provide royalties based on product sales. The Sancuso acquisition contributed $19 million in new assets, inclusive of around $4 million in inventory and $14 million in intangibles, with an estimated asset value of $9.5 million at the end of the second quarter. We provided $13.5 million at closing for the Sancuso acquisition and also paid $1.5 million in milestone payments, along with ongoing royalties based on brand sales. Looking at our balance sheet, as of June 30, 2025, we had $78.5 million in total assets, which includes $17.3 million in cash and cash equivalents. Total liabilities were $52.5 million, including $16.1 million for our credit facility. Total shareholders' equity was $26.3 million at the end of the quarter. We maintain a bank line of credit offering up to $20 million in capital, with an interest rate tied to benchmark term SOFR and a quarterly financial covenant, which we were compliant with at the end of the second quarter. Additionally, we are in the process of establishing new trading plans for our board members to purchase Cumberland shares throughout the year to increase their ownership in the company. Finally, I want to highlight that Cumberland holds over $52 million in tax net operating loss carryforwards, mainly due to the prior exercise of stock options. That concludes our financial report for the second quarter of 2025. Back to you, A.J.
Well, thank you, John. Overall, it's been a strong start to the year, and we've entered an exciting time for our company. We remain dedicated to our mission of working together to provide unique products that improve the quality of patient care. We're pursuing our mission by building a portfolio of FDA-approved brands with outstanding safety and efficacy profiles that can make a difference in patient lives. We continue to support our brands through our 3 dedicated sales divisions, each focused on strategic segments of the health care market. And we're encouraged by the progress of our ifetroban clinical studies as we continue to pursue therapeutic solutions for unmet medical needs. Looking ahead, we expect continued momentum across our approved brands, increased international contributions, further progress in our clinical pipeline and new opportunities through the select addition of new products. We have a lean, highly productive organization and the achievements outlined today were made possible by the dedication and fine efforts of our outstanding team. We look forward to providing updates on further developments as they unfold and as the year progresses. And now let's open the call to any questions. Operator, please proceed.
Thank you, everyone. That wraps up the company's presentation. We are now ready to take any questions. I see there are no questions at this moment, so I will hand it back to A.J. for closing remarks.
Well, thank you. I just want to tell everyone we appreciate you joining us for today's call. We do understand that many of our shareholders would like to have a private discussion with management. And if you would, please just reach out, and we'll be happy to get such a session scheduled and hold such a discussion. As always, thank you for your time and interest in our company, and we'll look forward to providing another update in the coming months.
Thank you. Ladies and gentlemen, that concludes today's call. If you would like to listen to a replay of the discussion, please visit the Investor Relations section on Cumberland's website. I would like to thank you for your participation. You may now disconnect.